Addex Therapeutics ADXN
NASDAQ ADXN
$2.96 +0.22 (+8.03%)
At close: Nov 10, 2026 · 4:00 PM EST

Addex Therapeutics (ADXN) Gains from Sales and Divestitures (2021)

Updated

Addex Therapeutics (ADXN) reported Gains from Sales and Divestitures of -$137.73 for Q4 2021, compared with -$5,522 a year earlier.

Analysis

Addex Therapeutics (ADXN) Gains from Sales and Divestitures (2021) Analysis & Trends

  • By year, Gains from Sales and Divestitures came in at -$5,522 in FY2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Addex Therapeutics 3.65 Mn -3.31 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 275.46
API Access

Addex Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=ADXN&period=max&api_key=YOUR_API_KEY